NVAX

NVX-CoV2373

COVID-19 Vaccine

Phase 2 (Interim immunogenicity and safety data)

Exp Date

Q4 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: NVX-CoV2373 in COVID-19 - Phase 2 (Interim immunogenicity and safety data)

  • ClinicalTrial.gov (NCT04368988): Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020


PRIOR DATA

PRESS RELEASES


COMPETITORS

  • TBA

MARKET

MECHANISM OF ACTION/RATIONALE

  • NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology

  • Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies

  • NVX-CoV2373 was shown to be highly immunogenic in animal models measuring spike protein-specific antibodies, antibodies that block the binding of the spike protein to the receptor and wild-type virus neutralizing antibodies. High levels of spike protein-specific antibodies with ACE-2 human receptor binding domain blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization.

  • (Source)

Updated by HC

#NVAX, #NVX-CoV2373, #COVID-19, #Vaccine

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

NVAX - Present COVID-19 Vaccin...

#NVAX "announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the Company’s COVID-19 vaccine, at the 2020 World Vaccine Congress Europe. The Congress t...

NVAX - Announces Publication o...

#NVAX today announced the publication in The New England Journal of Medicine of Phase 1 data from its Phase 1/2 clinical trial of NVX‑CoV2373, its COVID‑19 vaccine candidate adjuvanted with Matrix‑M™,...

MRNA - Announces Publication i...

#MRNA "announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of Medicine. This inter...

NVAX - Initiates Phase 2 Porti...

#NVAX - announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of #NVX-CoV2373 Interim immunogenicity an...

NVAX - Initiates Phase 3 Effi...

#NVAX announced that "it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The trial is being conducted in ...

NVAX - NVX-CoV2373 Phase 1 Dat...

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate. Scientific Summary: Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon